Genzyme Corp. said Tuesday the federal review of its offer to buy Canadian drugmaker AnorMed Inc. is complete.

Cambridge, Mass.-based Genzyme (Nasdaq GENZ) announced in October that it had inked an agreement to acquire AnorMed (Nasdaq ANOR) for $580 million in cash, worth about $13.50 per share.

The agreement will give Genzyme access to AnorMed's Mozobil, a treatment in late-stage clinical trials for the blood cancer multiple myeloma and non-Hodgkin's lymphoma.

Tuesday the companies said the expiration of the waiting period under the Hart-Scott- Rodino Antitrust Improvements Act of 1976.